Pharmaceutical company Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) announced on Friday the dosing of the first participants with OX640, an intranasal rescue medication for severe allergic reactions, in a new study involving subjects with allergic rhinitis (hay fever).

Completion of the study is expected in 2024 with results available in early 2025. Following positive phase 1 results showing equivalent absorption of epinephrine and effects on blood pressure and heart rate to an intramuscular auto-injector, Orexo advances OX640 development.

The new study, OX640-002, investigates epinephrine absorption in participants with and without nasal allergic symptoms. Conducted as a cross-over study in 30 participants, it includes four treatment periods, one involving allergen-induced nasal symptoms before OX640 treatment.

Comparisons will be made with OX640 absorption without allergen and a commercial intramuscular epinephrine product. Additionally, dose proportionality and effects on blood pressure and heart rate will be assessed to understand OX640's impact during anaphylaxis.